Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations | Chapter 7 | Medical Science: Trends and Innovations Vol. 4

This review aims to describe the main TKI inhibitor therapeutic agents used in targeted therapy of non-small cell lung cancer (NSCLC). Thus, we described: Osimertinib, Erlotinib, Gefitinib, Afatinib, Dacomitinib, Alectinib, Brigatinib, Lorlatinib, Crizotinib. Some observations were made on Entrectinib, although there is no experience in its use, among the molecular determinations approved for reimbursement in Romania is the determination of NTRK fusion, for which Entrectinib is recommended. A similar situation is with Dacomitinib. The side effects of these compounds that sometimes limit their use were briefly presented. Aspects relevant to clinical practice and no basic research nor pipeline research were briefly presented. In conclusion, it is demonstrated that for patients who have the appropriate mutations, deletions or gene fusions TKI represent an important role in the personalized therapy of patients with NSCLC.

 

Author (s) Details

Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania.

Please see the book here:- https://doi.org/10.9734/bpi/msti/v4/4098

Genetic Variants as a Prostate Cancer Risk | Chapter 11 | New Visions in Medicine and Medical Science Vol. 2

 Prostate cancer is one of the most frequent and potentially fatal cancers in males globally. Prostate cancer is a multifactorial disease caused by the interaction of one or more factors. In prostate cancer, several genetic alterations are involved. Due to their high complexity, these genetic modifications must be taken into consideration. These alterations not only account for a large portion of cancer deaths but also have a major impact on the effectiveness of medication. A significant challenge with advanced disease is that many hypothesized underlying pathways remain unknown or inadequately understood due to insufficient evidence. This chapter presents the available data on related pathways (DNA damage repair, androgen receptor and tumor suppression), examining each genetic anomaly (somatic copy number alterations, structural rearrangements, point mutations, SNPs, miRNA) and other related factors (P13K pathway, epigenetics, apoptosis inhibition, oxidative damage) that could be connected to the carcinogenesis of prostate cancer.

Author(s) Details:

Pradhumn,
Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana-124001, India.

Preeti Chauhan,
Department of Biotechnology, CCT, Chandigarh Group of Colleges, Landran, Mohali, Chandigarh-140307, India.

Shalu Ranga,
Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana-124001, India.

Ritu Yadav,
Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana-124001, India.

Please see the link here: https://stm.bookpi.org/NVMMS-V2/article/view/13806